Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Huge Debts And Divestment Plans, Wockhardt Chairman Habil Khorakiwala Exhorts Employees To Rise To The Challenge

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - These are tough times for Habil Khorakiwala, chairman of Wockhardt, one of India's largest pharmaceutical and biotechnology companies, as he deals with the worst financial crisis that any large Indian drug company has faced in the aftermath of the global economic meltdown

You may also be interested in...



Brakes May Be Put On Direct MNC Deals In India As Government Fears Threat To The Indian Drug Industry

MUMBAI - Acquisition of growing Indian firms by global pharmaceutical companies may get tough in the coming days as the government is brainstorming about how to clamp restrictions on buying controlling equity stakes in Indian entities through the automatic foreign direct investment route (FDI)

Brakes May Be Put On Direct MNC Deals In India As Government Fears Threat To The Indian Drug Industry

MUMBAI - Acquisition of growing Indian firms by global pharmaceutical companies may get tough in the coming days as the government is brainstorming about how to clamp restrictions on buying controlling equity stakes in Indian entities through the automatic foreign direct investment route (FDI)

Buzz Of Bids By GSK, Sanofi And Merck Get Louder As Piramal, Wockhardt Decline Sell-Off Talks

MUMBAI - Despite repeated denials, market buzz is getting louder that India's Piramal Healthcare is engaged in preliminary negotiations with multinational drug companies like GlaxoSmithKline, Sanofi-Aventis and Merck for a potential sell off

UsernamePublicRestriction

Register

MT126735

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel